AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Hormone Receptor-Positive Breast Cancer in 2026: ctDNA-Guided Switching and the Expanding Oral SERD Landscape
By Manpreet Kaur Chadha, MD
Care for hormone receptor-positive, HER2-negative advanced breast cancer is broadening well past the traditional aromatase inhibitor backbone.
Hormone Receptor-Positive Breast Cancer in 2026: ctDNA-Guided Switching and the Expanding Oral SERD Landscape
By Manpreet Kaur Chadha, MD
Care for hormone receptor-positive, HER2-negative advanced breast cancer is broadening well past the traditional aromatase inhibitor backbone.
Hormone Receptor-Positive Breast Cancer in 2026: ctDNA-Guided Switching and the Expanding Oral SERD Landscape
By Manpreet Kaur Chadha, MD
Care for hormone receptor-positive, HER2-negative advanced breast cancer is broadening well past the traditional aromatase inhibitor backbone.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Near-Complete Response to Immunotherapy Highlights an Overlooked Sun-Driven Sarcoma
By Athar Eysa, MD
Pleomorphic dermal sarcoma is a rare, ultraviolet-driven skin cancer that shares biology with better-known immunogenic tumors.
A Near-Complete Response to Immunotherapy Highlights an Overlooked Sun-Driven Sarcoma
By Athar Eysa, MD
Pleomorphic dermal sarcoma is a rare, ultraviolet-driven skin cancer that shares biology with better-known immunogenic tumors.
A Near-Complete Response to Immunotherapy Highlights an Overlooked Sun-Driven Sarcoma
By Athar Eysa, MD
Pleomorphic dermal sarcoma is a rare, ultraviolet-driven skin cancer that shares biology with better-known immunogenic tumors.
Peripheral T-Cell Lymphoma: Why "Not Otherwise Specified" Should Be a Last Resort, Not a Default
By Yumeng Zhang, MD
T-cell lymphomas account for roughly 10% of non-Hodgkin lymphoma in Western countries, and up to about 20% in parts of Asia, a genuine epidemiologic difference.
Peripheral T-Cell Lymphoma: Why "Not Otherwise Specified" Should Be a Last Resort, Not a Default
By Yumeng Zhang, MD
T-cell lymphomas account for roughly 10% of non-Hodgkin lymphoma in Western countries, and up to about 20% in parts of Asia, a genuine epidemiologic difference.
Peripheral T-Cell Lymphoma: Why "Not Otherwise Specified" Should Be a Last Resort, Not a Default
By Yumeng Zhang, MD
T-cell lymphomas account for roughly 10% of non-Hodgkin lymphoma in Western countries, and up to about 20% in parts of Asia, a genuine epidemiologic difference.
Surgery or Radiation for Stage III Lung Cancer? The Better Question Is Not Which, But When Do We Decide
By Neel Chudgar, MD
The surgery-versus-radiation debate in stage III NSCLC is increasingly the wrong framing; the better approach is starting with the best available systemic therapy
Surgery or Radiation for Stage III Lung Cancer? The Better Question Is Not Which, But When Do We Decide
By Neel Chudgar, MD
The surgery-versus-radiation debate in stage III NSCLC is increasingly the wrong framing; the better approach is starting with the best available systemic therapy
Surgery or Radiation for Stage III Lung Cancer? The Better Question Is Not Which, But When Do We Decide
By Neel Chudgar, MD
The surgery-versus-radiation debate in stage III NSCLC is increasingly the wrong framing; the better approach is starting with the best available systemic therapy
ER-Positive Breast Cancer in 2026: New Oral Endocrine Agents and the Case for ctDNA-Guided Switching
By Natalie Chen, MD
Despite substantial treatment advances, roughly a quarter of patients with early-stage ER-positive breast cancer still develop recurrence within five years
ER-Positive Breast Cancer in 2026: New Oral Endocrine Agents and the Case for ctDNA-Guided Switching
By Natalie Chen, MD
Despite substantial treatment advances, roughly a quarter of patients with early-stage ER-positive breast cancer still develop recurrence within five years
ER-Positive Breast Cancer in 2026: New Oral Endocrine Agents and the Case for ctDNA-Guided Switching
By Natalie Chen, MD
Despite substantial treatment advances, roughly a quarter of patients with early-stage ER-positive breast cancer still develop recurrence within five years
Leptomeningeal Disease Is Becoming More Common, and Also More Treatable
By Morana Vojnic, MD, MBA
Leptomeningeal disease (LMD) is becoming more common simply because patients with actionable mutations are living longer
Leptomeningeal Disease Is Becoming More Common, and Also More Treatable
By Morana Vojnic, MD, MBA
Leptomeningeal disease (LMD) is becoming more common simply because patients with actionable mutations are living longer
Leptomeningeal Disease Is Becoming More Common, and Also More Treatable
By Morana Vojnic, MD, MBA
Leptomeningeal disease (LMD) is becoming more common simply because patients with actionable mutations are living longer
Rethinking Glioblastoma Care: Methylation Status, Tumor Treating Fields, and IDH Inhibitors
By Jerome Graber, MD, MPH
Glioblastoma outcomes with temozolomide depend heavily on MGMT methylation status, a distinction worth revisiting given how often it gets lost in practice.
Rethinking Glioblastoma Care: Methylation Status, Tumor Treating Fields, and IDH Inhibitors
By Jerome Graber, MD, MPH
Glioblastoma outcomes with temozolomide depend heavily on MGMT methylation status, a distinction worth revisiting given how often it gets lost in practice.
Rethinking Glioblastoma Care: Methylation Status, Tumor Treating Fields, and IDH Inhibitors
By Jerome Graber, MD, MPH
Glioblastoma outcomes with temozolomide depend heavily on MGMT methylation status, a distinction worth revisiting given how often it gets lost in practice.
Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show
By Carolina Schinke, MD
CAR-T cell therapy and bispecific antibodies have transformed relapsed multiple myeloma, but sequencing matters.
Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show
By Carolina Schinke, MD
CAR-T cell therapy and bispecific antibodies have transformed relapsed multiple myeloma, but sequencing matters.
Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show
By Carolina Schinke, MD
CAR-T cell therapy and bispecific antibodies have transformed relapsed multiple myeloma, but sequencing matters.
The Silent Ecosystem Within Clinical Trials
By Zoë Swainson, MHA
Clinical trial outcomes do not emerge solely by science. They also emerge from an invisible ecosystem of trust, coordination, compassion and operational excellence.
The Silent Ecosystem Within Clinical Trials
By Zoë Swainson, MHA
Clinical trial outcomes do not emerge solely by science. They also emerge from an invisible ecosystem of trust, coordination, compassion and operational excellence.
The Silent Ecosystem Within Clinical Trials
By Zoë Swainson, MHA
Clinical trial outcomes do not emerge solely by science. They also emerge from an invisible ecosystem of trust, coordination, compassion and operational excellence.